Susquehanna lowered its price target on Teva Pharma (NYSE: TEVA) to $14.00 (from $20.00) while maintaining a Positive rating.

Analyst Andrew Finkelstein notes Q3 showed further challenges.

Analyst PT Change

Teva Pharma (TEVA) Gains as Billionaire Blavatnik Considers Buying Large StakeNovember 6, 2017 6:41 AM Teva Pharma (TEVA) PT Lowered to $13 at Goldman SachsNovember 6, 2017 5:28 AM Top five unique options volume: FB SBUX FL GE TEVANovember 3, 2017 9:56 AM Deutsche Bank Downgrades Teva Pharma (TEVA) to HoldNovember 3, 2017 5:54 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Nov 02November 2, 2017 4:10 PM Teva Pharma (TEVA) PT Slashed to $10 at Cantor FitzgeraldNovember 2, 2017 1:39 PM Teva Pharma (TEVA) Plunges to Fresh Low, Down 16%November 2, 2017 9:33 AM Teva Reports Third Quarter 2017 Financial ResultsNovember 2, 2017 8:02 AM UPDATE: Teva Pharma (TEVA) Misses Q3 EPS by 4c, Q4 Guidance Comes in LightNovember 2, 2017 7:00 AM